Prothena Corporation plc (NASDAQ:PRTA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET
Company Participants
Eric Endicott - Senior Vice President, Corporate Affairs and Communications
Gene Kinney - President and Chief Executive Officer
Hideki Garren - Chief Medical Officer
Tran Nguyen - Chief Financial Officer and Chief Strategy Officer
Wagner Zago - Chief Scientific Officer
Conference Call Participants
Michael Yee - Jefferies
Neena Bitritto-Garg - Citi
Charles Duncan - Cantor Fitzgerald
Jay Olson - Oppenheimer
Brian Abrahams - RBC Capital Markets
Jason Butler - JMP Securities
Operator
Good afternoon. My name is Audra and I will be your conference operator today. At this time, I would like to welcome everyone to the Prothena's Fourth Quarter and Full Year 2022 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Mr. Eric Endicott, Prothena's Senior Vice President, Corporate Affairs and Communications. Please go ahead.
Eric Endicott
Thank you operator. Good afternoon, everyone and welcome to Prothena's investor conference call to review our business progress, our fourth quarter and full year 2022 financial results and our 2023 financial guidance. Please review the press release we issued earlier today, which is available on our website at prothena.com and is also attached to a Form 8-K filed today with the SEC.
On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide introductory remarks followed by an overview of Prothena's portfolio and development strategy as we continue advancing towards becoming a fully integrated commercial biotechnology company. Following Gene's opening remarks; Dr. Hideki Garren, our Chief Medical Officer will provide an overview of the significant achievements and progress made in 2022 across our entire portfolio. Tran Nguyen, our Chief Financial Officer and Chief Strategy Officer, will then review our financial results for the fourth quarter and full year of 2022 and we'll discuss our 2023 financial guidance. Gene will then provide closing remarks and then we will open the call up for a Q&A session where Dr. Bogner Zago, our Chief Scientific Officer and Susanna Mesa, our Senior Vice President Strategy and operations will also be participants.
Before we begin, I would like to remind you that during today's presentation we will be making forward-looking statements that are subject to certain risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with our forward-looking statements, please see our press release issued today as well as our most recent filings with the SEC. We disclaim any obligation to update our forward-looking statements.